BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Indication :

Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))


Sponsor :

BMS


Phase :

I, II


Ligne :

1ère ligne (pour NSCLC 1ère ligne IO-naive)


Traitement :

Relatlimab plus Nivolumab plus Ipilimumab


Site :

CHUV


Contact(s) :
Eleonora Ghisoni
Investigateur Principal

CHUV
Service d'Immuno-Oncologie

Rue du Bugnon 46
Lausanne
1011

0213143854
do.ion.ref@chuv.ch

Primary objective :

To investigate safety and tolerability of relatlimab triple combinations in distinct cohorts of participants with advanced malignant tumors.


Inclusion criteria :
  • 18 Years and older (Adult, Older Adult)
  • Male, female
  • Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
  • Available tumor tissue for biomarker analysis
  • Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1

Exclusion criteria :
  • Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease
  • Participants with a history of interstitial lung disease (ILD) / pneumonitis
  • Prior malignancy active within the previous 3 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer